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Background: Diabetes mellitus is a major public health problem with significant morbidity and mortality. Evidence
based guidelines have been proposed to reduce the micro and macrovascular complications, but studies have
shown that these goals are not being met. We sought to compare the adherence to the American Diabetes
Association guidelines for measurement and control of glycohemoglobin (A1c), blood pressure (BP), lipids (LDL)
and microalbuminuria (MA) by subspecialty and primary care clinics in an academic medical center.
Methods: 390 random charts of patients with diabetes from Family Practice (FP), Internal Medicine (IM) and
Diabetes (DM) clinics at Michigan State University were reviewed.
Results: We reviewed 131, 134 and 125 charts from the FP, IM and DM clinics, respectively. DM clinic had a higher
percentage of patients with type 1 diabetes 43/125 (34.4%) compared with 7/131 (5.3%) in FP and 7/134 (5.2%) in
IM clinics. A1c was measured in 99%, 97.8% and 100% subjects in FP, IM and DM clinics respectively. B.P. was
measured in all subjects in all three clinics. Lipids were checked in 97.7%, 95.5% and 92% patients in FP, IM and DM
clinics respectively. MA was measured at least once during the year preceding the office visit in 85.5%, 82.8% and
76.8% patients in FP, IM and DM clinics respectively. A1C was controlled (<7%) in 38.9, 43.3, 28.8% of patients in the
FP, IM and DM clinics, respectively (p = 0.034). LDL was controlled (<100 mg/dl or 2.586 mmol/l) in 71.8, 64.9, 64%
of patients in the FP, IM and DM clinics, respectively. MA was controlled (<30 mg/gm creatinine) in 60.3%, 51.5%
and 60% patients in FP, IM and DM clinics respectively (P = 0.032). BP was controlled (<130/80) in 59.5, 67.2 and
52.8% patients in the FP, IM and DM clinics, respectively.
Conclusion: Testing rates for A1C, LDL, and MA were high, in both subspecialty and primary care clinics. However,
the degree of control was not optimal. Significantly fewer patients in the DM clinic had A1c <7%, the cause of
which may be multifactorial.
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Diabetes mellitus is a major public health issue in the
US. In 2010, 25.8 (8.3%) million persons had diabetes,
out of which 7.0 million were undiagnosed [1]. This
number has increased to 29 million in 2012, an increase
of 13% [2]. Diabetes related annual healthcare expenses
are estimated to be 245 billion dollars with the medical
expenditure for a person with diabetes being 2.3 times* Correspondence: Ved.Gossain@hc.msu.edu
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unless otherwise stated.higher than a non-diabetic [3]. Clinical trials have con-
sistently demonstrated a decrease in micro vascular
complications with optimal glycemic, blood pressure and
lipid management [4-7] and possible reduction in macro
vascular disease [8]. Evidence based guidelines have been
proposed to decrease morbidity and mortality from dia-
betes [9,10]. The American Diabetes Association (ADA)
publishes these guidelines annually, and these guidelines
are widely followed in the primary care and in the spe-
cialized diabetes clinics. However, the adherence to these
current practice guidelines has been less than optimalis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ADA guidelines were being followed in our primary care
clinics and also in the subspecialized diabetes clinic. Sub-
specialists in diabetes undergo extensive training in the
management of diabetes and specialized diabetes centers
often provide a multidisciplinary approach to diabetes care
with provision of medical, dietary and other care under
one roof. However, existing studies evaluating specialist
vs. primary care in the treatment of diabetes have yielded
inconsistent results [12-24]. We hypothesized that special-
ized diabetes clinics provide superior quality of care and
better patient outcomes compared to primary care clinics.
Our primary aim was to compare the adherence to Ameri-
can Diabetes Association guidelines for measurement and
control of glycohemoglobin (A1c) blood pressure (BP),
lipids (LDL) and microalbuminuria (MA) by Internal
Medicine, Family Practice and subspecialty clinics in an
academic medical center. The study began in November
2010 and was completed by August 2012.
Methods
This study was approved by the Michigan State Univer-
sity and Sparrow Hospital Institutional Review Boards.
ADA recommends that A1c should be determined at
least two times a year in patients who are meeting treat-
ment goals and who have stable glycemia control and
quarterly in patients whose therapy has changed or who
are not meeting glycemic goals. For blood pressure con-
trol, the ADA recommends that hypertension should be
treated to a systolic blood pressure goal of <140 mmHg
and a diastolic goal of <80 mmHg. Lower systolic blood
pressure targets such as <130 mmHg may be appropriate
for certain individuals, such as younger patients, if it can
be achieved without undue treatment burden [10]. How-
ever, in the earlier versions of the ADA guidelines, the
recommended blood pressure target was <130/80 [9], and
we have used that level to determine if blood pressure was
controlled or not. For lipid levels, the ADA recommends
that, individuals without overt cardiovascular disease, the
goals should be: LDL cholesterol <100 mg/dL, HDL chol-
esterol >50 mg/dL for women and >40 mg/dL for men
and triglycerides <150 mg/dL [10].
Study population
390 randomly selected charts of adult patients with dia-
betes from diabetes (DM), Internal Medicine (IM) and
Family practice (FP) clinics at Michigan State University
(MSU) were retrospectively reviewed. The DM clinic is
located in one of our affiliated hospitals and provides
subspecialty care to a referral population of approxi-
mately 1 million around Lansing, the capital city of
Michigan. Diabetes care at this center is delivered by 2
board certified endocrinologists (who are also full time
faculty members of the MSU Department of Medicine),3 endocrinology fellows, 2 nurse-practitioners, and 2 di-
etitians. All non-physician health care providers at the
center are certified diabetes educators. Patients at the
DM clinic are typically seen only by referral from an-
other physician and are transferred back to their primary
care physician when their diabetes care is optimized.
The IM and FP clinics are located in the outpatient facil-
ities of MSU and cater to patients with a variety of ill-
nesses including diabetes. Providers at the Internal
Medicine clinic and Family Practice clinics are board
certified internists, family practitioners as well as resi-
dent physicians who work under the supervision of an
attending physician.
Data collection
Retrospective review was conducted on 390 randomly
selected patient charts at the 3 clinics from November
2010 to August 2012. We used a standardized chart ab-
straction form to collect and record data. Two of the au-
thors (DR and LS) abstracted the charts. Data collected
included age, gender, race, BMI, smoking status, type of
diabetes, self-glucose monitoring, Metformin, other anti-
diabetic medications, insulin, aspirin, ACEi (Angiotensin
Converting Enzyme Inhibitors), angiotensin receptor
blockers (ARBs), and statin use. We also assessed the
measurement and control of A1C, LDL, BP and microal-
buminuria during the one year period preceding their
most recent visit. The laboratory data (A1C, lipid levels,
and microalbuminuria) collected were done as part of
routine clinical care of the study subject and were done
at local clinical laboratories. Data was collected retro-
spectively for up to 12 months prior to the most recent
visit for each patient.
Statistical analysis
Data was analyzed to determine the average age, BMI of
the patient population, gender distribution, percentage
of smokers, type 1 vs type 2 diabetics and also if self-
glucose monitoring was being performed. We also ana-
lyzed the proportion of patients taking Metformin, insu-
lin, aspirin, ARBs, ACEi, statins at the time of the most
recent visit. We analyzed the data to determine the
measurement and degree of control of A1c, BP and
lipids and microalbuminuria. Results are reported in per-
centages. Descriptive statistics were computed as means
and standard deviations for continuous variables and as
frequencies for categorical variables. We used ANOVA
for continuous variables and chi square test for dichot-
omous variables. Logistic regression models were used
to assess the factors affecting binary dependent variables.
P values less than .05 were considered significant. The
data analysis was performed by an independent biostatis-
tician at the Michigan State University Center for statis-
tical training and computing, using SPSS, version 17.
Table 2 Control of diabetes parameters
Variable FP (n = 131) IM (n = 134) DM (n = 125) P value
A1c Measured 130 (99.2%) 131 (97.8%) 125 (100)
Controlled <7% 51 (38.9%) 58 (43.3%) 36 (28.8%) 0.034
BP Measured 131 (100%) 134 (100%) 125 (100%)
Controlled <130/80) 78 (59.5%) 90 (67.2%) 66 (52.8%) 0.062
LDL Measured 123 (93.9%) 123 (91.8%) 112 (89.6%)
Controlled <100 94 (71.8%) 87 (64.9%) 80 (64%) 0.552
Microalbumin
Measured
112 (85.5%) 111 (82.8%) 96 (76.8%)
Controlled** 79 (60.3%) 69 (51.5%) 66 (60%) 0.032*
Values are absolute numbers with % in ( ).
*P < .05 was considered significant.
**Defined as <30 mg/gm creatinine.
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Results were obtained from 390 patient charts of which
131 were from the family Practice clinic (FP), 134 from
the Internal Medicine clinic (IM) and 125 from the spe-
cialist diabetes center clinic (DM).
Demographics
Baseline characteristics are shown in Table 1. Patients in
the DM clinic with a mean age of 52.82 ± 16.02 were sig-
nificantly younger compared to the patients in other two
groups. There was no statistically significant difference
between clinics as it relates to the gender distribution,
smokers or those with a BMI > 30 kg/m2.
There were significantly greater number of type 1 dia-
betes patients in the DM clinic (34.4%) compared to the
FP (5.3% and IM (5.2%) clinics (p < 0.01). Similarly insu-
lin use (79.2%) and self glucose monitoring (68.8%) were
higher in the DM clinic (p < 0.01). Use of aspirin (53.6%)
and Metformin (34.4%) was significantly less among the
DM clinic patients (p < 0.01). There was no significant
difference in the use of Angiotensin converting Enzyme
Inhibitors (ACEi)/Angiotensin Receptor Blockers (ARBs)
or statins between the three clinics.
Control of diabetes parameters
Hemoglobin A1c
Hemoglobin A1c was measured at least once in the pre-
ceding 6 months prior to the last visit in 99.2% of the
patients in FP clinic, 97.8% of patients in IM clinic and
100% of the DM clinic patients. Significantly fewer
patients (28.8%) in the DM clinic had their A1c controlled
(less than 7%) compared to 38.9% in the FP clinic and
43.3% in the IM clinic (p = 0.034) (see Table 2).Table 1 Baseline characteristics
Variable FP (n = 131) IM (n = 134) DM (n = 125) P value
Mean age 61.00 ± 11.00 62.11 ± 12.88 52.82 ± 16.02 <0.001*
Male 74 (56.5%) 61 (45.5%) 72 (57.6%) 0.095
Female 57 (43.5%) 73 (54.5%) 53 (42.4%)
BMI >30 71 (54.1%) 66 (49.2%) 58 (46.4%) 0.092
Smoker 14 (10.7%) 18 (13.4%) 21 (16.8%) 0.306
Type 1 7 (5.3%) 7 (5.2%) 43 (34.4%) <0.001*
Type 2 124 (94.7%) 127 (94.8%) 82 (65.6%)
Self glucose
monitoring
58 (45.0%) 67 (50.0%) 86 (68.8%) <0.001*
Metformin 107 (81.6%) 85 (63.5%) 43 (34.4%) <0.001*
Insulin 34 (26.1%) 39 (29.1%) 99 (79.2%) <0.001*
Aspirin 104 (79.4%) 84 (62.7%) 67 (53.6%) <0.001*
ACEI/ARB 105 (80.2%) 105 (78.4%) 97 (77.6%) 0.876
Statin 92 (70.2%) 87 (64.9%) 81 (64.8%) 0.569
Age is given as mean ± SD.
Other values are absolute numbers with percentage in ( ).
*Statistically significant.Blood pressure
Blood pressure was recorded in all patients in the three
clinics. There was no significant difference in blood
pressure control (less than 130/80) between the three
clinics (p = 0.062) with 59.5% of FP clinic patients, 67.2%
of IM clinic patients and 52.8% of DM clinic patients
being under control (see Table 2).
Lipids
Lipids were checked at least once in 97.7%, 95.5% and
92% of the FP, IM and DM clinic patients respec-
tively. LDL level was at goal (less than 100 mg/dl or
2.586 mmol/l) in 71.8% of FP; 64.9% of IM and 64% of
DM clinic patients (p = 0.552). (Mean ± SD), LDL level
was 83.97 (29.91); 88.51 (34.17) and 87.21 (26.86) mg/dL
in FP, IM and DM clinics respectively. Fifty seven per-
cent, 59.1% and 68.7% of the FP, IM and DM clinic
patients respectively had their triglycerides at target
(less than 150 mg/dL). HDL was controlled (more than
50 mg/dL for women and more than 40 mg/dL for men)
in 38.9%, 45.5% and 48.8% of the FP, IM and DM clinics
respectively (see Table 2).
Microalbumin
Microalbumin was measured at least once during the
year preceding the office visit in 85.5% of FP clinic
patients, 82.8% of IM clinic patients and 76.8% of DM
clinic patients (see Table 2).
Factors affecting the control of diabetes care
A multivariate statistical analysis controlling for age,
gender, race, BMI, smoking status, and type of diabetes
to predict effects on A1c, lipids, B.P and microalbumi-
nuria was performed (see Table 3).
For A1c, additionally insulin use and self glucose mon-
itoring was also included in the model and the analysis
revealed that insulin use was the only significant factor
affecting A1C control. Insulin use was associated with
Table 3 Results of logistic regression models showing
odds ratios
A1c BP Lipid Micro-
albuminuria
Controlled Uncontrolled Controlled Controlled
OR OR OR OR
Gender
(ref. Female)
Male 1.38 1.15 1.56* 1.12
AGE 0.99 0.99 1.03** 0.99
BMI 1.01 0.97** 1.01 1.02
Smoker
(ref. Ex-smoker)
Smoker 1.17 1.10 1.35 0.874
Non-smoker 0.97 1.39 0.88 0.094
Not Documented 1.13 2.32 0.65 1.646
Diabetes
(ref. Type 1)
Type 2 1.37 1.46 0.93 0.46
Self-Glucose
Monitor (ref. No)
Yes
1.00 NA NA 2.59***
Not Documented 0.80 1.62
Insulin (ref. No) NA NA NA
Yes 4.37***
LDL Cholesterol
(ref. = < 100)
NA NA
>100 1.89** 0.95
ACE inhibitor
(ref. Not taking )
NA NA
Took 0.70 0.57
ARB (ref.
Not taking )
NA NA
Took 0.59 0.74
Beta blocker
(ref. Not taking )
NA NA NA
Took 0.86
Diuretic (ref.
Not taking )
NA NA NA
Took 0.54*
CCB (ref. Not
taking)
NA NA NA
Took 0.73
Number of
Medicine Taken
NA 1.10 NA 0.77**
BP (ref.
control = <130/80)
NA NA
Table 3 Results of logistic regression models showing
odds ratios (Continued)
Uncontrolled
> 130/80
0.56** 0.94
A1c (ref.
Uncontrolled)
NA NA NA
control 0.94
Note: Level of significance: ***p-value < .001; **p-value < .05; *p-value < .1.
CCB = Calcium channel blockers.
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likely to have A1C ≥7% (OR = 4.37, p = 0.01).
With regard to BP, additionally, LDL control, use of
antihypertensive drugs and the total number of drugs
used was included in the model. The analyses revealed
that patients on diuretics, were more likely to have con-
trolled B.P (<130/80) (OR = 1.7, p = 0.05) and those with
LDL > 100 were more likely to have uncontrolled BP
(>130/80) (OR = 1.89, p = 0.02).
There was also an association of age with controlled
LDL levels in that older subjects were more likely to
have LDL >100 mg/dl (OR = 1.03, p = 0.01).
For microalbuminuria, the additional controlled fac-
tors were use of ACEi/ARBs, total number of antihyper-
tensive drugs A1c, lipids, self glucose monitoring and
control of B.P. Self glucose monitoring was associated
with controlled microalbuminuria (<30 mg/gm creatin-
ine; OR =2.59, P < 0.01). Subjects taking increased num-
ber of antihypertensive drugs were less likely to have
controlled microalbuminuria (OR = 0.77, p < 0.01).
Discussion
The main findings of our study are that the ADA guide-
lines are being adhered to in our primary care (FP, IM)
and diabetes specialty clinic. We have also evaluated the
degree of control of some of the diabetes care parame-
ters and compared our results to the data presented by
Ali et al. [11] where they analyzed the quality of diabetes
care in the US from 1999 to 2010.
In our study, A1c was measured in 97.8 to 100% of the
patients depending on the clinic; however, only 28.8 to
43.3% of the patients achieved a target A1c below 7%.
This is lower than that reported by Ali et al. [11] during
the time period of 2007 to 2010, where 52.2% subjects
were reported to have an A1c <7%. They also reported
that the glycemic control defined as A1c <7% improved
by 9.4 percentage points (95% CI 3.0-15.8 from the years
1999–2010.
The ADA guidelines from 2010 [9] which were the
standards of care during the duration of this study rec-
ommend a blood pressure target less than 130/80 mm of
Hg. In our study, BP was measured 100% of the time in
all the patients, but controlled in 52.8% to 67.2% of
patients among the three clinics. This is higher than the
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(51.3%) during 2007 to 2010 [11]. Nationally the blood
pressure control improved by 11.7 percentage points
(95% CI 5.7-17.7) from 1999–2010.
The ADA recommends checking a fasting lipid profile
at least annually and every 2 yearly in those with con-
trolled values. In our study, lipid profile was checked at
least once annually in 89.6 to 93.9% of the patients
based on the clinic. LDL was controlled in 64 to 71.8%,
triglycerides were controlled in 57 to 68.7% of the
patients and HDL was controlled in 39.8 to 53% of the
patients. Our LDL control rates appear to be better than
the 56.8% control rate of the national diabetes popula-
tion in the US, for years 2007–2010 [11]. Again, nation-
ally the control of LDL, defined as <100 mg/dL improved
by 20.8 percentage points (95% CI 11.6-30.0) between
1999 and 2010. In our study, 76.8 to 85.5% patients had
their micro albumin measured but microalbuminuria was
controlled in 51.5% patients in the IM clinic. This differ-
ence was statistically significant (p = 0.032) compared to
the other two groups where the microalbuminuria was
controlled in 60% patients. The rate of controlled
microalbuminuria is lower than that reported rate in the
US diabetic population during 2007 to 2010, where
69.8% of survey participants were free of microalbumi-
nuria (<30 mg/gm creatinine).
There were no significant differences in the gender
distribution, number of smokers and obese between the
three clinics in our study. With regards to age, the DM
clinic population in our study was significantly younger
compared to the FP and IM clinics. This is consistent
with the findings of several other studies [13-18]. This
could be explained by the constitution of higher number
of type 1 diabetics in the subspecialty clinics. Our study
results show significantly higher number of type 1 dia-
betics in the DM clinic similar to the study by Grant
et al. [18] Insulin use was significantly higher in the DM
clinic in keeping with the findings of several other stud-
ies [14,16,18]. We also found significantly increased rate
of self-glucose monitoring by patients of the DM clinic
similar to the findings of Zgibor et al. [19].
We found that ADA guidelines are being followed in
the majority of our study population in the monitoring
of A1c, blood pressure, lipids and urine albumin excre-
tion. However, the degree of control of these parameters
is not optimal. The number of patients with an A1c
lower than 7 was significantly lower in our DM clinic
compared to IM and FP clinics. There was no significant
difference in the control of BP and lipids, but the control
of MA was significantly lower in the IM clinic.
Several studies comparing specialist and general prac-
titioner care in diabetes failed to show a consistent su-
periority of specialist care in diabetes outcomes. In
results from the Medical Outcomes Study, Greenfieldet al. [20] compared glycemic and BP control, visual
function, foot ulcers and albumin excretion rate among
endocrinology, general internist and family practice
clinics, there was no significant difference in quality
measures based on physician specialty except improved
foot ulcer prevalence in endocrinologist care. No differ-
ence in adjusted outcome and process measures was
found between specialist and primary care in another
study by Greenfield et al. [14]. Similarly, Ismail et al.
[21] conducted an observational study which showed
that patients seen in specialist clinics had a higher A1c
at baseline than those receiving routine primary care,
but there was no difference in the rate of improvement
with each visit.
There are also other studies demonstrating that spe-
cialty care leads to better performance in diabetes
management. A retrospective study by Ho et al. [12]
comparing specialist and generalist care in the VA set-
ting found that the patients under specialist care had
better processes of care including recording of A1c,
blood pressure, foot and eye exams, but there was no
measurement of outcomes in this study. Zgibor et al.
[19] studied type 1diabetic participants in the Pitts-
burgh Epidemiology of Diabetes Complications Study
and found significantly lower mean A1c levels in those
receiving specialist care. In a long term follow up study
from the same population they also found that prior
specialist use was significantly protective against the
development of overt nephropathy, neuropathy and
weakly protective against coronary artery disease [13].
Suwattee et al. [15] found that diabetes clinic per-
formed better in A1c, BP and LDL outcomes compared
to resident and faculty care in general medicine clinics.
Although process measures were significantly more in
favor of specialist care in a study by De Berardis et al.
[16] there was no difference in diabetes outcomes ex-
cept total cholesterol. Uchigata et al. [22] studied type
1 diabetics in Japan and found that those receiving spe-
cialist care were significantly less likely to develop end
stage renal disease and less likely to die. In a study by
Grant et al. [18]. Endocrinology clinic had better A1c,
BP and LDL values and urine albumin screening. Shah
et al. [17] showed better A1c values in specialist care
while Sone et al. [23] found that baseline A1c values
significantly improved under specialist management.
In terms of health care expenditure, Levetan et al. [24]
showed that for patients admitted with diabetic ketoa-
cidosis, Endocrinologist care reduced the length of
stay, hospital expenditure and readmission rate.
Although, from our study, it appears that the glycemic
control is worse in a specialist clinic, there are several
factors which could explain this. It could be due to refer-
ral bias, wherein, patients who are referred to specialist
care are poorly controlled when they are referred. Patients
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physicians leading to fragmentation of care and deferment
of some services to other providers. Specialists are also
more likely to individualize glycemic targets depending on
co morbid conditions and therefore assessing control
based on A1c less than 7% may not be valid for the com-
plexity of patients seen at the DM clinic. Our data also
does not reflect the duration of specialist care for the
patients. In the management of a chronic condition likely
diabetes, long term follow up is needed to assess improve-
ment in outcomes. This is especially relevant since longi-
tudinal follow up studies [13,16,21,22] of patients under
specialist care have shown improvement in diabetes
parameters and outcomes over time. Also, it has been the
practice of our DM clinic to return the patients who have
achieved stable and improved glycemic control back to
their primary care providers. Therefore, patients who are
not well controlled remain in the DM clinic and this
may partly explain the presence of fewer patients with
A1c <7%.
Our study does have limitations. While a randomized
controlled trial is the ideal type of study to measure the
impact of an intervention, ours is a retrospective obser-
vational study. Our data only reflect the measures at a
single point. We do not have follow up data and there-
fore it is not possible to gauge change over time. We do
not have information on all the comorbidities of the
patients which can affect their metabolic control and
glycemic targets. Our study also does not include data
about patients receiving care from other specialists,
which may lead to physicians’ inaction with regards to
medication adjustment for uncontrolled blood pressure
and lipids.
Conclusion
In our study the specialist clinic patients were younger
with a higher proportion of type 1 diabetics and insulin
users. There were no significant differences in the gen-
der and weight distribution, smoking status, BP and
LDL control. Although A1c appeared better in FP and
IM clinics compared to DM clinic, the nature of the
study precludes the inference that there is no difference
between diabetes care provided in a specialty center vs.
a general clinic, although other studies have shown im-
provement in diabetes parameters with specialist care,
but unequivocal evidence of improved mortality is lack-
ing. Further long term studies to assess the impact of
subspecialty care on diabetes are warranted.
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